Aldeyra Therapeutics, Inc., a biotechnology leader in immune-mediated disease therapies, has announced encouraging results from its Phase 2 clinical trial evaluating ADX-629 in patients with
As reported by drugs.com, at the American College of Rheumatology (ACR) Convergence congress, Novartis presented encouraging results from its Phase III NEPTUNUS-1 and NEPTUNUS-2 trials,
Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Utah, has announced that its investigational drug, ofirnoflast (HT-6184), has received Orphan Drug Designation (ODD) from
In a groundbreaking moment for transplant medicine, Massachusetts General Hospital (MGH) has concluded its second successful xenotransplantation of a genetically modified pig kidney into a
A collaborative team from Arc Institute, Gladstone Institutes, and UCSF has unveiled a groundbreaking epigenetic editing platform that could revolutionize next-generation cell therapies. Published in
Older adults are at heightened risk for severe anaphylaxis but are less likely than younger adults to receive the recommended treatment of epinephrine, according to
Editor’s Note: We’re honored to share this patient story-share by Jess Ippolito, originally published by our friends at Stork Genetics. To see the article in
Xspray Pharma, the developer of the drug dasatinib, was recently issued a Complete Response Letter (CRL) by the FDA while waiting for corrective actions, according
Sanofi has announced encouraging results from a Phase 2 clinical trial of efdoralprin alfa, an investigational therapy for alpha-1 antitrypsin deficiency (AATD), a rare genetic
I’ve suffered from Crohn’s and fibromyalgia since I was a child. I was told I had “food allergies.” My fibromyalgia was hidden from me until
Grieving families who have lost loved ones to severe allergic reactions are calling for urgent reforms to the way deaths from anaphylaxis are investigated in
BridgeBio Pharma has reported decisive success in a pivotal phase 3 trial for its rare disease drug BBP-418, aimed at treating limb-girdle muscular dystrophy type
Sanofi has announced encouraging results from its Phase 2 ElevAATe clinical trial evaluating efdoralprin alfa (SAR447537), a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, for
Merck & Co has taken a significant step forward in its immunology pipeline by initiating Phase IIb clinical studies for tulisokibart (MK-7240), its investigational therapy
This patient story is sponsored by AVEO Pharmaceuticals, Inc. and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our
Women living in areas of the United States with poor air quality, particularly neighborhoods with high motor vehicle emissions, face a greater risk of developing
A significant shift could soon be underway in the management of severe allergic reactions, as new research highlights intranasal (IN) adrenaline as a compelling, needle-free
I’ll never forget the day I was told I have ulcerative colitis. Suddenly, I had both an answer and a thousand new questions. There are
Transthyretin amyloid cardiomyopathy (ATTR-CM) happens when a protein called TTR builds up in the heart, making it harder to pump blood. It can cause fatigue, swelling, or shortness of breath but these symptoms are easy to mistake for something else.
That’s why stories and awareness matter! The more people who recognize the signs, the more likely it is to get caught early. If you're interested in sharing your story, click here: bit.ly/4dV7gru
#ATTRCM #AmyloidosisAwareness #HeartHealth #RareDisease #ShareYourStory #PatientWorthy
Did you know? Combined Small-Cell Lung Carcinoma (C-SCLC) blends features of two major lung cancer types within the same tumor. Let’s use Lung Cancer Awareness Month to spread knowledge and support everyone affected by rare lung cancers. #LungCancerAwarenessMonth #RareLungCancer #CSCLC #LungCancer #PatientWorthy
#ShareYourStory with us here: bit.ly/4dV7gru
A new ALS drug has begun accelerated development after a surge in early-stage clinical activity. Read more here:
patientworthy.com/2025/11/11/als-drug-development-accelerates-spotlight-on-medicinovas-mn-166/
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
